Hepatocellular Carcinoma — Trial of TG4023 Combined With Flucytosine in Liver Tumors
Citation(s)
A Phase I, Open-label, Dose-escalating Study of the Safety or Percutaneous Intra-tumoral Injection of TG4023 (MVA-FCU1) Combined With Systemic Administration of 5-fluorocytosine in Patients With Primary or Secondary Hepatic Tumors.